ClinicalTrials.gg
CompletedNCT00423579Updated May 22, 2024Results posted

The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)

A Phase 4 interventional study of Ezetimibe/Simvastatin 10/20 mg and simvastatin 40 mg in Hypercholesterolemia and Coronary Disease, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2006, registered Jan 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Hypercholesterolemia by Organon & Co. — none open to participants now, none under way, none of them phase 3. Hypercholesterolemia · Organon & Co..

Enrollment
66th of 81
120 · median 321
Started
2006
with 6 others
Phase 4
19 of 91
none open now
Registered
34th of 91
by date

Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 66th largest by enrollment of the 81 interventional ones that give a count, is one of 7 that started in 2006, is one of 19 in phase 4, and was the 34th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 91 studies in Hypercholesterolemia by Organon & Co. is open now. The open studies under Hypercholesterolemia, anywhere →

Where they have run

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies in Hypercholesterolemia by Organon & Co. as a file.
02

Study summary

This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe/simvastatin 10/20 mg when administered daily versus doubling the dose of simvastatin to 40 mg in patients with hypercholesterolemia and coronary heart disease.

03

Conditions studied

  • Hypercholesterolemia
  • Coronary Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have documented coronary heart disease (CHD). For the purposes of this study, CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing); history of myocardial infarction; history of percutaneous coronary intervention [PCI] (primarily PCI with or without stent placement); symptomatic peripheral vascular disease (claudication); documented history of atherothrombotic cerebrovascular disease; and/or documented history of unstable angina or non-Q wave myocardial infarction.
  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • History of myocardial infarction (heart attack).
  • Subjects must be >= 18 years and \<= 75 years of age.
  • Subjects must have an LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to \<= 4.1 mmol/L (160 mg/dL) at the time of randomization (Visit 3/Baseline Visit).
  • Subjects must have triglyceride concentrations of \< 3.99 mmol/L (350 mg/dL) at (Visit 3 Baseline Visit).
  • Subject must be currently taking simvastatin 20 mg daily.
  • Subjects must have liver transaminases ( [alanine aminotransferase], AST [aspartate aminotransferase]) \< 50% above the , with no active liver disease, and CK (creatine kinase) \< 50% above the upper limit of normal at Visit 3 (Baseline Visit).
  • Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis) must be within normal limits or clinically acceptable to the investigator at Visit 3 (Baseline Visit).
  • Subjects must have maintained a cholesterol-lowering diet and exercise program for at least 4 weeks prior to the study and be willing to continue the same diet and exercise program during the study.
  • Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline Visit).
  • Women receiving hormonal therapy, including hormone replacement, any estrogen antagonist/agonist, or oral , must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the duration of the study.
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed intrauterine device [IUD], condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Subjects must be free of any diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
  • Subjects must understand and be able to adhere to the dosing and visit schedules, and must agree to remain on their cholesterol-lowering diet and their exercise regimen for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose (BMI = weight [kg]/height2 [m]) is >= 35 kg/m\^2 at Visit 3 (Baseline Visit).
  • Subjects who consume > 14 alcoholic drinks per week. (A drink is: a can of beer, glass of wine, or single measure of spirits).
  • Any condition or situation which, in the opinion of the investigator, might pose a risk to the subject or interfere with participation in the study.
  • Women who are pregnant or nursing.

Exclusion Criteria: subjects who have the following medical conditions:

  • Congestive heart failure defined by (NYHA) as Class III or IV.
  • Uncontrolled cardiac arrhythmia.
  • Myocardial infarction, acute coronary insufficiency, coronary artery bypass surgery, or angioplasty within 3 months of Visit 3 (Baseline Visit).
  • Unstable or severe peripheral artery disease within 3 months of Visit 3 (Baseline Visit).
  • Newly diagnosed or currently unstable angina pectoris (chest pain).
  • Uncontrolled hypertension (treated or untreated) with systolic blood pressure > 160 mm Hg or diastolic > 100 mm Hg at Visit 3 (Baseline Visit).
  • Type I or Type II diabetes mellitus.
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, i.e., secondary causes of hyperlipidemia, such as secondary hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above ) at Visit 3. Subjects with a history of hypothyroidism who are on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible for enrollment if TSH levels are within normal limits at Visit 3 (Baseline Visit).
  • Impaired renal function (creatinine > 2.0 mg/dL) or nephrotic syndrome at Visit 3 (Baseline Visit).
  • Disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation.
  • Known (HIV) positive.
  • Cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas).
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.

Exclusion Criteria: subjects who are on any of the following concomitant medications:

  • Subjects who have not observed the designated for any of the prohibited medications.
  • Subjects who have not stopped taking various prohibited medications for a minimum period of time before Visit 3, including amiodarone hydrochloride (6 months) and probucol (12 months).
  • Subjects currently consuming large amounts of grapefruit juice (> 1 liter/day).
  • Oral , unless used as replacement therapy for pituitary/adrenal disease and the subject is on a stable regimen for at least 6 weeks prior to Visit 3 (Baseline Visit).
  • Subjects who are currently using cardiovascular medication (e.g. antihypertensive, antiarrhythmic) and have not been on a stable regimen for at least 6 weeks prior to Visit 3 (Baseline Visit) and it is expected to change during the study.
  • Subjects who are currently using psyllium, other fiber-based laxatives, and/or any other over-the-counter (OTC) therapy known to affect serum lipid levels (phytosterol margarine), and have not been on a stable regimen for at least 5 weeks prior to study entry Visit 3 (Baseline Visit) and who do not agree to remain on this regimen throughout the study.
  • Subject who are currently using orlistat or sibutramine.
  • Subjects who are currently using amiodarone hydrochloride.
  • Subjects who are currently using danazol.
  • Subjects who are currently using coumarin anticoagulants (warfarin).
  • Subjects who are using (at the Screening Visit / Visit 1) any statin other than simvastatin 20 mg, or ezetimibe alone or in combination with any statin (including the fixed combination with simvastatin).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo

    Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment

    Drug: Ezetimibe/Simvastatin 10/20 mg

  • Active comparator
    Ezetimibe/Simvastatin placebo + Simvastatin 40 mg

    Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.

    Drug: simvastatin 40 mg

Interventions

  • DrugEzetimibe/Simvastatin 10/20 mg

    1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks

  • 1 tablet containing 40 mg of simvastatin per day for 6 weeks

06

What researchers measure

Primary outcomes

  1. Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks

    Percentage change in LDL C from baseline to endpoint after 6 weeks of treatment.

    Time frame: Baseline and 6 weeks

07

Results

Posted Aug 25, 2009

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe/Simvastatin 10/20 mg + Simvastatin PlaceboEzetimibe/Simvastatin Placebo + Simvastatin 40 mg
Started6060
Completed5656
Not completed44
Withdrew: Lost to follow-up30
Withdrew: Protocol violation13
Withdrew: Diagnosis of diabetes01

Outcome measures

PrimaryChange in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks

Percentage change in LDL C from baseline to endpoint after 6 weeks of treatment.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks
percentage changeEzetimibe/Simvastatin 10/20 mg + Simvastatin PlaceboEzetimibe/Simvastatin Placebo + Simvastatin 40 mg
Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks-26.5 ± 9.5-11.9 ± 13.6
Statistical analysis
  • Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo vs Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg · Student's t test for independent data · p = 0.0000 · Mean difference (net): -14.5 · 95% CI -18.9 to -10.1Difference in percentage change in mean LDL-C values (change from baseline to week 6) between the two treatment groups. (Ezetimibe \[EZ\]/Simvastatin \[S\] \[10/20mg\] + S \[placebo\] group minus the EZ/S \[10mg/placebo\] + S \[40mg\] group)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo—0/60 (0%)0/60 (0%)
Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg—1/60 (1.7%)0/60 (0%)
Most frequent serious events
Most frequent serious events
EventEzetimibe/Simvastatin 10/20 mg + Simvastatin PlaceboEzetimibe/Simvastatin Placebo + Simvastatin 40 mg
Transient Ischemic AttackCardiac disorders0/601/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe/Simvastatin 10/20 mg + Simvastatin PlaceboEzetimibe/Simvastatin Placebo + Simvastatin 40 mgTotal
Mean61.3 ± 8.462.1 ± 7.861.7 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe/Simvastatin 10/20 mg + Simvastatin PlaceboEzetimibe/Simvastatin Placebo + Simvastatin 40 mgTotal
Female262450
Male303262
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Averna M, Zaninelli A, Le Grazie C, Gensini GF. Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. J Clin Lipidol. 2010 Jul-Aug;4(4):272-8. doi: 10.1016/j.jacl.2010.05.002. Epub 2010 Jun 1. PubMed 21122660 ↗
  • Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2010 Jul 27;9:80. doi: 10.1186/1476-511X-9-80. PubMed 20663203 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2006 to primary completion in Mar 2008, 20 months.

Results were first posted in Aug 2009, 1 year 5 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
StartActual
Jul 1, 2006
Primary completionActual
Mar 1, 2008
CompletionActual
Mar 1, 2008
Results first posted
Aug 25, 2009
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00423579
Lead sponsor
Organon and Co
Collaborators
Schering-Plough
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Jul 1, 2006
Primary completion
Mar 1, 2008
Completion
Mar 1, 2008
Results posted
Aug 25, 2009
Last update
May 22, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion